Literature DB >> 14986890

Protein profiling in daunorubicin-induced cardiomyopathy.

M Adamcová1, V Pelouch, V Gersl, J Kaplanová, Y Mazurová, T Simůnek, I Klimtová, R Hrdina.   

Abstract

The aim of this paper was to study the protein remodelling of the left ventricle following repeated administration of either daunorubicin (DNR) or DNR in combination with the cardioprotective agent dexrazoxane (DXZ). The experiment was carried out on three groups of Chinchilla male rabbits: 1. DNR (3 mg/kg i.v.), 2. DNR (3 mg/kg i.v.) + DXZ (60 mg/kg i.p.), and 3. the control group (saline 1 ml/kg i.v. in the same schedule). The drugs were given once weekly, max. 10 administrations. Protein fractions were isolated by stepwise extraction from the samples of the left ventricle. In the DNR-group, the concentrations of both, metabolic and contractile proteins were significantly reduced, while the amount of collagen was significantly higher in comparison with the control group. In the group treated with DNR and DXZ, the concentrations of individual protein fractions (except metabolic proteins) were comparable to those of the control group, which confirms a significant cardioprotective effect of DXZ. The changes of protein profiling corresponded to functional examination of both cardiac parameters (EF, dP/dt(max), PEP: LVET index) and histological examination. These data should be used in further studies dealing with evaluation of cardiotoxic and, possibly, cardioprotective effects of new drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14986890

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  2 in total

1.  [P4HA2 promotes occurrence and progression of liver cancer by regulating the PI3K/Akt/mTOR signaling pathway].

Authors:  L Shang; W Jiang; J Zhang; W Wu
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

2.  Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.

Authors:  Tianjiao Wang; Xueli Fu; Tianzhi Jin; Lu Zhang; Bowen Liu; Yue Wu; Feifei Xu; Xue Wang; Kai Ye; Weiying Zhang; Lihong Ye
Journal:  EBioMedicine       Date:  2019-07-02       Impact factor: 8.143

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.